UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform

Molecules (Basel, Switzerland), 2021-03, Vol.26 (7), p.1912

2021

Volltextzugriff (PDF)

Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept

Biopharmaceutics & drug disposition, 2017-03, Vol.38 (2), p.139-154

2017

Volltextzugriff (PDF)

Determining the potency of inhibition of five GRAS or dietary compounds to inhibit the oxidative and conjugative metabolism of buprenorphine

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S53-S53

2018

Volltextzugriff (PDF)

Use of GRAS or dietary compounds to improve the oral bioavailability of buprenorphine

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S25-S25

2018

Volltextzugriff (PDF)

Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

Drug metabolism and disposition, 2020-10, Vol.48 (10), p.1008-1017

2020

Volltextzugriff (PDF)

Entering the era of computationally driven drug development

Drug metabolism reviews, 2020-04, Vol.52 (2), p.283-298

2020

Volltextzugriff (PDF)

Predicting the Potential of Major Cannabinoids and Their Metabolites to Precipitate Cytochrome P450‐mediated Drug Interactions

The FASEB journal, 2021-05, Vol.35 (S1), p.n/a, Article fasebj.2021.35.S1.03383

2021

Volltextzugriff (PDF)

A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics

Pharmacology & therapeutics (Oxford), 2019-09, Vol.201, p.25-38

2019

Volltextzugriff (PDF)

Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform

Drug design, development and therapy, 2020-01, Vol.14, p.2307-2317

2020

Volltextzugriff (PDF)

Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability

Biopharmaceutics & drug disposition, 2019-01, Vol.40 (1), p.18-31

2019

Volltextzugriff (PDF)

Inhibition of Oxidative and Conjugative Metabolism of Buprenorphine Using Generally Recognized As Safe (GRAS) Compounds or Components of Dietary Supplements

Maharao, Neha

2017

Volltextzugriff (PDF)

Simultaneous Quantitation of Buprenorphine and Its Metabolites Using LC-MS

Spectroscopy, 2016-07, p.15

2016

Volltextzugriff (PDF)

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(11)
Dissertationen
(1)

Sprache

Englisch
(12)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform

Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept

Determining the potency of inhibition of five GRAS or dietary compounds to inhibit the oxidative and conjugative metabolism of buprenorphine

Use of GRAS or dietary compounds to improve the oral bioavailability of buprenorphine

Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

Entering the era of computationally driven drug development

Predicting the Potential of Major Cannabinoids and Their Metabolites to Precipitate Cytochrome P450‐mediated Drug Interactions

A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics

Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform

Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability

Inhibition of Oxidative and Conjugative Metabolism of Buprenorphine Using Generally Recognized As Safe (GRAS) Compounds or Components of Dietary Supplements

Simultaneous Quantitation of Buprenorphine and Its Metabolites Using LC-MS

Suchergebnisse filtern